[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vaso-occlusive-crisis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vaso-occlusive-crisis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,77,105,127],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100656599","phase-4-adaptive-platform-trial-for-pain-management-in-sickle-cell-vaso-occlusive-crisis-100656599",false,"NCT07826988","Adaptive Platform Trial for Pain Management in Sickle Cell Vaso-Occlusive Crisis","Adaptive Platform Trial for Pain Management During Vaso-Occlusive Crisis in Adult Patients With Sickle Cell Disease","PAMAVOC","Inclusion Criteria:\n\n* Adult patients (age ≥18 years)\n* Diagnosed with major sickle cell syndrome (SS homozygous, SC or Sβ° or Sβ+ thalassemia compound heterozygous)\n* Hospitalized and presenting with a vaso-occlusive crisis (VOC), defined as acute pain or tenderness affecting at least one part of the body, including the limbs, ribs, sternum, head (skull), spine, and\u002For pelvis, not attributable to other causes\n* Requiring intravenous morphine or its derivatives\n* Informed consent obtained from the patient (or from a trusted support person, family member, or relative), or emergency inclusion procedure in cases where the patient is unable to consent and no trusted support person, family member, or relative is available\n\nExclusion Criteria:\n\n* Refusal to participate\n* Pregnant or breastfeeding patient\n* Administration of one of the interventional group treatments within 4 hours prior to inclusion\n* Intravenous morphine treatment for more than 24 hours\n* Patient already included in the study within the previous 3 months\n* Patient receiving long-term opioid therapy\n* Not affiliated with a social security scheme, or patient under State Medical Aid (AME)\n* Patient under legal protection measures (guardianship \u002F family authorization with representation mandate \u002F future protection mandate) or under supervised guardianship (curatelle)\n* Patient deprived of liberty\n* Participation in another clinical trial involving a drug\n* Participation in the PAMAVOC trial within the previous 3 months\n* Contraindication to standard VOC treatment:\n* Hypersensitivity to opioids\n* Opioid-induced hyperalgesia, defined by increased pain on nociceptive testing, topographic extension, or the onset of allodynia with increasing opioid doses\n* Renal impairment, defined as creatinine clearance ≤30 mL\u002Fminute\n* Hepatocellular impairment, defined as prothrombin time \\\u003C40%\n* Impaired consciousness, defined as a Glasgow Coma Scale score ≤13\u002F15\n\nExclusion from a Specific Intervention (randomization possible to other study arms):\n\n* Hypersensitivity to the active substance or to any of the excipients\n* Respective contraindications to nefopam, tramadol, ketoprofen, and ketamine, as described in their respective Summaries of Product Characteristics (SmPC)","ALL","18 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Sickle cell disease (SCD) is a severe hemoglobinopathy, characterized by recurrent vaso-occlusive crises (VOC) causing intense pain and frequent hospitalizations in adult patients. Current French and British guidelines recommend rapid administration of strong opioids, primarily through patient-controlled analgesia (PCA), as the reference treatment for hospitalized patients experiencing VOC. However, opioid use is associated with dose-dependent adverse effects, including nausea, constipation, pruritus, sedation, and hypoventilation, the latter representing a risk factor for acute chest syndrome.\n\nThe hypothesis underlying this study is that multimodal analgesia-combining morphine PCA with co-analgesics such as paracetamol-can significantly reduce morphine consumption during hospitalization compared to opioid-only analgesia, while maintaining effective pain control. Although several co-analgesic agents (paracetamol, NSAIDs, nefopam, tramadol, ketamine) are recommended by expert guidelines, including those from the American Society of Hematology (2020) and French recommendations (2025), the level of evidence supporting their use in adult sickle cell patients remains low or non-existent for most agents, with no randomized controlled trials available for nefopam, tramadol, or ketamine.\n\nUsing an adaptive platform design, this trial aims to compare multiple analgesic strategies against standard opioid-based care, generating higher-quality evidence to optimize pain management protocols for adult patients experiencing VOC",[27,28],"Sickle Cell Disease","Vaso-occlusive Crisis",[30,31,32,33,34],"Sickle cell disease","Multimodal Analgesia","Patient-Controlled Analgesia","Pain Management","Vaso-Occlusive Crisis","NOT_YET_RECRUITING","2026-09-11",{"date":38,"type":39},"2026-09-18","ACTUAL",{"date":41,"type":21},"2026-10-01",{"date":43,"type":21},"2030-01-01",{"name":45,"class":46},"Assistance Publique - Hôpitaux de Paris","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100312910","effect-of-virtual-reality-technology-for-pain-management-of-vaso-occlusive-crisis-in-patients-with-sickle-cell-disease-100312910","NCT03353584","Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease","Pain Management of Vaso-Occlusive Crisis in Children and Young Adults With Sickle Cell Disease-Effect of Virtual Reality Technology","Inclusion Criteria:\n\n* Participant must have sickle cell disease (any genotype), documented in the St. Jude medical record.\n* Participant must be seeking care for acute VOC pain at St. Jude Children's Research Hospital.\n* Participant age must be ≥ 6 years and ≤ 25 years.\n* English speaking\n\nExclusion Criteria:\n\n* Prior randomization in this study.\n* Patients are currently enrolled on another pain management interventional trial for the presenting pain crisis.\n* Mild pain (score \\\u003C4), or pain for which treatment with opioid is not indicated.\n* Pain in combination with other clinical symptoms that require additional interventions, including fever with focus, acute chest syndrome, acute injury, or splenic sequestration.\n* Developmental or psychiatric disorders like autism, claustrophobia or other disabilities like vision and hearing defects etc. that preclude the use of a head mounted device.\n* Inability or unwillingness of research participant or legal guardian\u002F representative to give written informed consent.","6 Years","25 Years",{"count":57,"type":21},76,[59],"NA","Acute vaso-occlusive crisis (VOC) is the most common complication in patients with sickle cell disease (SCD) and pain related to VOC is often inadequately treated. This is a phase II randomized controlled clinical trial evaluating the efficacy of virtual reality technology when added to standard pain management for patients with sickle cell disease who are experiencing acute pain crisis in the ambulatory care setting. Patients will be randomized to receive either standard management only or standard management in addition to virtual reality therapy. The remainder of care for the painful event will continue per institutional standards according to clinical indication, including reassessment and documentation of pain and additional doses of pain medicines by intravenous (IV) or oral route. Pain scores and opioid requirement will be measured and compared across treatment arms, along with the outcomes of discharge from clinic versus admission to the inpatient unit.\n\nPRIMARY OBJECTIVE: To assess the efficacy of virtual reality (VR) technology in reducing pain at 30 minutes after intervention during an acute vaso-occlusive crisis in patients with sickle cell disease. Primary endpoint will be change in pain scores in Standard versus VR arms, between the first pain assessment at the time of presentation and the subsequent pain assessments up to 30 minutes after intervention.\n\nSecondary Objectives:\n\n* To compare total opioid consumption from the time of presentation to the time of discharge from acute care setting in Standard versus VR arms.\n* To assess the efficacy of virtual reality (VR) technology in reducing pain at 60 minutes after the first IV medication administered or 60 minutes after completion VR during an acute vaso-occlusive crisis in patients with sickle cell disease.",[27,28],[63,64,65],"Virtual reality","Pain","Nonpharmacological","RECRUITING","2026-05-14",{"date":69,"type":39},"2026-05-18",{"date":71,"type":39},"2018-02-05",{"date":73,"type":21},"2026-11",{"name":75,"class":46},"St. Jude Children's Research Hospital",2,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":84,"maxAge":18,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100608385","outcomes-of-vaso-occlusive-crisis-in-pediatric-sickle-cell-disease-100608385","NCT07200869","Outcomes of Vaso-occlusive Crisis in Pediatric Sickle Cell Disease","Vaso-occlusive Crisis Incidence and Outcomes in a Pediatric Sickle Cell Population","Inclusion Criteria:\n\n* Children aged 1-18 years. Confirmed diagnosis of sickle cell anemia by hemoglobin electrophoresis or high-performance liquid chromatography .\n\nHistory of at least one hospital visit or admission for vaso-occlusive crisis\n\nExclusion Criteria:\n\n* Patients with other hemoglobinopathies (e.g., thalassemia). Patients with incomplete medical records. Children with coexisting chronic diseases that may confound pain crises .","1 Year",{"count":86,"type":21},25,"OBSERVATIONAL","This study aims to assess the incidence and clinical outcomes of vaso-occlusive crises in pediatric patients with sickle cell disease. Data will be collected and analyzed to identify risk factors and related complications.",[27,28],[91,92,93,94],"Pediatric","Sickle Cell Anemia","Incidence","Outcomes","2025-09-23",{"date":97,"type":39},"2025-10-01",{"date":99,"type":21},"2025-10",{"date":101,"type":21},"2027-11",{"name":103,"class":46},"Assiut University",1,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100530047","phase-3-intranasal-sufentanil-for-analgesia-of-severe-sickle-cell-vaso-occlusive-pain-crisis-in-the-pediatric-100530047","NCT06181695","Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric","Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric Emergency Department: a Double Blind Randomized Versus Placebo Controlled Trial","INVOPE","Inclusion Criteria:\n\nAt inclusion visit:\n\n* Sickle-cell disease = Hemoglobin SS or SC or Sß-thalassemia\n* Age \\\u003C 18 years old\n* Weight \\> 10 kgs\n* Registered with the social security scheme (or State Medical Aid - AME) or his\u002Fher beneficiaries\n* Informed consent of the holder (s) of the exercise of parental authority\n* Age \\\u003C 18 years old\n\nAt randomisation visit\n\n* Presenting to the ED with vaso-occlusive crisis: migratory bone pain, which may occur in the limbs, spine, thorax, pelvis, skull; or crisis known as such by the patient.\n* Severe pain determined at triage, defined as:\n\n  * EVENDOL ≥ 10\u002F15 in children aged 0-8 years or\n  * NRS-11 ≥ 7\u002F10 in children aged 8 years to less than 18 years\n* Informed consent of the holder (s) of the exercise of parental authority signed at inclusion visit\n\nExclusion Criteria:\n\n* At inclusion visit\n\n  * Known cirrhosis\n  * End-stage renal disease requiring kidney dialysis\n  * Known hypersensitivity or contraindication to sufentanil or any of the excipients\n  * Contraindication to morphine\n  * Facial malformation, epistaxis, blocked or traumatised nose\n  * Severe asthma\n  * Patient's or parent's refusal to participate\n  * Participation in another interventional trial\n  * Parents who do not speak French\n\nAt randomization visit\n\n* Known cirrhosis\n* End-stage renal disease requiring kidney dialysis\n* Known hypersensitivity or contraindication to sufentanil or any of the excipients\n* Contraindication to morphine\n* Facial malformation, epistaxis, blocked or traumatised nose\n* Severe asthma\n* Patient's or Parent's refusal to participate or withdrawal of parental consent\n* Participation in another interventional trial\n* Patient has already been randomised to the INVOPE trial during a previous VOC\n* Strong opioids received \\\u003C6 hours (morphine, oxycodone, hydromorphone, fentanyl, sufentanil, nalbuphine)\n* Respiratory failure (tachypnea; bradypnea; paradoxical breathing; grunting; head-bobbing; nasal flaring; retractions (subcostal, suprasternal, intercostal, sternal))\n* Oxygen saturations below 95% on initial assessment\n* Pneumonia requiring oxygen therapy\n* Hemodynamic disorders: tachycardia, hypotension\n* Altered conscious state as defined by a Glasgow Coma score less than 15\n* Positive urinary pregnancy test for woman of childbearing potential (postpubertal female with sexual activity)\n* Nasal or sinus surgery within 6 months before randomisation\n* High fever \\> 39°C\n* Sign of intolerance of acute anaemia\n* Description by the patient (or the parents) of the unusual nature of the attack",{"count":114,"type":21},182,[116],"PHASE3","Sickle cell disease (SCD) is characterized by an abnormal hemoglobin, the main protein in the red blood cell. From the first months of life, acute obstruction of the vessels of the microcirculation manifests as intense and unpredictable recurrent episodes of severe pain. In the Emergency Department (ED), patients presenting with a vaso-occlusive crisis (VOC) required a rapid evaluation and administration of pain relief therapies and hydration.\n\nthis strategy is based on an intranasal (IN) administration of Sufentanil at the initial management of children with VOC, followed by morphine intravenous (IV) relay as soon as possible, compared to the usual care procedure with IV morphine as soon as possible.\n\nThe hypothesis is that the use of this IN opioid at the beginning of the management of children with VOC can reduce the time before being pain relieved. Indeed, the IN administration make it easier and faster to administer.",[28],"2023-12-12",{"date":121,"type":39},"2023-12-26",{"date":123,"type":21},"2024-05-02",{"date":125,"type":21},"2027-05-29",{"name":45,"class":46},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":135,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":138,"studyType":87,"phases":4,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":104},"100468151","study-of-erythrocyte-parameters-and-hypercoagulability-in-sickle-cell-disease-scd-tga-100468151","NCT05376046","Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease (SCD-TGA)","Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease","SCD-TGA","Inclusion Criteria:\n\n* Sickle cell disease\n\nExclusion Criteria:\n\n* \\\u003C18 years\n* pregnancy\n* Patient under protective guardianship or curatorship",true,{"count":137,"type":21},200,"5 Years","Sickle cell disease (SCD) is an inherited haemoglobinopathy disorder caused by mutations in HBB gene with amino-acid substitution on β globin chain. The consequence is synthesis of altered haemoglobin S (HbS) which polymerises in red blood cell (RBC) at deoxygenated state. SCD is associated with chronic haemolytic anaemia, vaso-occlusive crisis (VOC) leading to frequent hospitalisation.\n\nThe aim of the study was to to investigate whether a combination of routine laboratory biomarkers of haemolysis could be used to predict VOC development in confirmed SCD patients.",[27,28],[142,143,144,145,146],"sickle cell disease","vaso-occlusive crisis","reticulocyte count","thrombin generation assay","hypercoagulability","2022-05-17",{"date":149,"type":39},"2022-05-24",{"date":151,"type":39},"2018-09-01",{"date":153,"type":21},"2026-09-01",{"name":155,"class":46},"BILLOIR"]